CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® ...

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -

Related Keywords

United States ,Wayne Chu ,Chris Ogden ,Sean Mccarthy ,Stephanie Ascher ,Nasdaq ,Drug Administration ,Twitter ,Bristol Myers Squibb ,Amgen ,Cytomx Therapeutics Inc ,Linkedin ,Investigational New Drug ,Quarterly Report ,Cytomx Therapeutics ,Media Contact ,Region ,